Details

Autor(en) / Beteiligte

• Monge, Maria C., M.D., M.A.T
• Forman, Sara F., M.D
• McKenzie, Nicole M
• Rosen, David S., M.D., M.P.H
• Mammel, Kathleen A., M.D
• Callahan, S. Todd, M.D., M.P.H
• Hehn, Rebecca, M.A
• Rome, Ellen S., M.D., M.P.H
• Kapphahn, Cynthia J., M.D., M.P.H
• Carlson, Jennifer L., M.D
• Romano, Mary E., M.D., M.P.H
• Malizio, Joan B., M.S.N
• Bravender, Terrill D., M.D., M.P.H
• Sigel, Eric J., M.D
• Rouse, Mary R., M.D
• Graham, Dionne A., Ph.D
• Jay, M. Susan, M.D
• Hergenroeder, Albert C., M.D
• Fisher, Martin M., M.D
• Golden, Neville H., M.D
• Woods, Elizabeth R., M.D., M.P.H

Titel

Use of Psychopharmacologic Medications in Adolescents With Restrictive Eating Disorders: Analysis of Data From the National Eating Disorder Quality Improvement Collaborative

Ist Teil von

• Journal of adolescent health, 2015-07, Vol.57 (1), p.66-72

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2015

Quelle

Access via ScienceDirect (Elsevier)

Beschreibungen/Notizen

• Abstract Purpose Psychopharmacologic medications are often prescribed to patients with restrictive eating disorders (EDs), and little is known about the frequency of use in adolescents. We examined the use of psychopharmacologic medications in adolescents referred for treatment of restrictive ED, potential factors associated with their use, and reported psychiatric comorbidities. Methods Retrospective data from the initial and 1-year visits were collected for patients referred for evaluation of restrictive ED at 12 adolescent-based ED programs during 2010 (Group 1), including diagnosis, demographic information, body mass index, prior treatment modalities, and psychopharmacologic medications. Additional data regarding patients' comorbid psychiatric conditions and classes of psychopharmacologic medications were obtained from six sites (Group 2). Results Overall, 635 patients met inclusion criteria and 359 had 1-year follow-up (Group 1). At intake, 20.4% of Group 1 was taking psychopharmacologic medication and 58.7% at 1 year ( p  ≤ .0001). White, non-Hispanic race ( p  = .020), and prior higher level of care ( p < .0001) were positively associated with medication use at 1 year. Among Group 2 (n = 256), serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors use was most common, and 62.6% had a reported psychiatric comorbidity. Presence of any psychiatric comorbidity was highly associated with medication use; odds ratio, 10.0 (5.6, 18.0). Conclusions Adolescents with restrictive ED treated at referral centers have high rates of reported psychopharmacologic medication use and psychiatric comorbidity. As more than half of this referral population were reported to be taking medication, continued investigation is warranted to ensure the desired outcomes of the medications are being met.